Critical Contrast: Interpace Biosciences (OTCMKTS:IDXG) vs. Acutus Medical (NASDAQ:AFIB)

Valuation & Earnings

This table compares Interpace Biosciences and Acutus Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.21	$24.58 million	($0.02)	-90.00
Acutus Medical	$7.16 million	0.00	-$81.66 million	($0.11)	N/A

Interpace Biosciences has higher revenue and earnings than Acutus Medical. Interpace Biosciences is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Interpace Biosciences and Acutus Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	65.25%	219.07%	105.05%
Acutus Medical	-272.74%	-311.64%	-11.57%

Insider and Institutional Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 56.9% of Acutus Medical shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by company insiders. Comparatively, 5.2% of Acutus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Interpace Biosciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Acutus Medical has a beta of 6.08, indicating that its stock price is 508% more volatile than the S&P 500.

Summary

Interpace Biosciences beats Acutus Medical on 7 of the 10 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.